[HTML][HTML] Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials
P Zhao, H Zhen, H Zhao, L Zhao, B Cao - BMC cancer, 2022 - Springer
… A retrospective study indicated that adjuvant gefitinib could … DFS compared to adjuvant
chemotherapy in patients with … effect for dichotomous outcomes such as adverse events and …
chemotherapy in patients with … effect for dichotomous outcomes such as adverse events and …
[HTML][HTML] Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
S Tanaka, J Uchino - Translational Lung Cancer Research, 2019 - ncbi.nlm.nih.gov
… adverse events were rash in the erlotinib group (2/50 patients, 4%… Regarding treatment
efficacy for advanced-stage lung cancer… 1104 trials and a retrospective study (14,15). The former …
efficacy for advanced-stage lung cancer… 1104 trials and a retrospective study (14,15). The former …
Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
S Wang, J Li - OncoTargets and therapy, 2019 - Taylor & Francis
… , and paronychia the most common adverse events (AEs) reported in clinical and real-world …
efficacy of afatinib in routine clinical practice. Several retrospective analyses have compared …
efficacy of afatinib in routine clinical practice. Several retrospective analyses have compared …
Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer
ZY Xu, JL Li - OncoTargets and therapy, 2019 - Taylor & Francis
… of serious or fatal adverse events, and/or lead to reductions in therapeutic efficacy. Citation1
… Subsequently, two retrospective studies in patients with EGFR mutations receiving either of …
… Subsequently, two retrospective studies in patients with EGFR mutations receiving either of …
[HTML][HTML] … Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
CH Chiu, MC Lin, YF Wei, GC Chang, WC Su… - Targeted Oncology, 2023 - Springer
… experienced one or more treatment-emergent adverse events (… , phase III study compared
the efficacy and safety of RAM … retrospective nature of the study are major limitations of this …
the efficacy and safety of RAM … retrospective nature of the study are major limitations of this …
[HTML][HTML] The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung …
… 2023, we retrospectively recruited patients diagnosed with advanced-… had comparable
efficacy, with gefitinib exhibiting a more … and adverse effects of afatinib and dacomitinib in NSCLC …
efficacy, with gefitinib exhibiting a more … and adverse effects of afatinib and dacomitinib in NSCLC …
… for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non–small cell lung cancer positive for the …
N Haratake, H Hayashi, M Shimokawa, Y Nakano… - Clinical lung cancer, 2022 - Elsevier
… (OS) compared with gefitinib or erlotinib in patients with the … The primary objective of the
study is to evaluate the efficacy of … Adverse events are recorded on the basis of the National …
study is to evaluate the efficacy of … Adverse events are recorded on the basis of the National …
Real-world data of osimertinib in patients with pretreated non-small cell lung cancer: a retrospective study
Y Mu, P Xing, X Hao, Y Wang, J Li - Cancer Management and …, 2019 - Taylor & Francis
… We assessed efficacy and safety of osimertinib in patients with … Adverse events (AEs) were
graded according to National … 13 and our retrospective study were superior compared with …
graded according to National … 13 and our retrospective study were superior compared with …
[HTML][HTML] Outcome differences between first-and second-generation EGFR inhibitors in advanced EGFR mutated NSCLC in a large population-based cohort
SC Lau, N Chooback, C Ho, B Melosky - Clinical Lung Cancer, 2019 - Elsevier
… all patients with advanced non–small-cell lung cancer who … based retrospective review to
compare differences in OS between … The adverse event profile of gefitinib and erlotinib are well-…
compare differences in OS between … The adverse event profile of gefitinib and erlotinib are well-…
[HTML][HTML] … ) combination therapy and osimertinib for untreated EGFR-mutated advanced non-small cell lung cancers: A systematic review and network meta-analysis
Y Lei, J Duan, Q Zhang, Q Li - Medicine, 2023 - journals.lww.com
… This paper is a retrospective review and does not involve … was used to compare the efficacy
and specific toxicity of all … PFS and OS were extracted for adverse events (TEAEs) occurring …
and specific toxicity of all … PFS and OS were extracted for adverse events (TEAEs) occurring …